Clinical Trial

Prevalence of Tapia's Syndrome in Weaning Unit

Study acronym: PRESTIO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated November 7, 2025 completion). Its status may not reflect the trial's current state.
Summary
Tapia syndrome is a rare and poorly understood pathology. It is defined by a concomitant attack of the recurrent (branch of X) and hypoglossal (XII) nerves of peripheral or central origin. It is characterized by the paralysis of a vocal cord and the ipsilateral half of tongue. This damage is most often unilateral but it can also be bilateral. It results in dysphonia and swallowing disorders. Tapia syndrome is a rare and poorly understood pathology. To date, less than 100 cases have been described in the literature. Previous works are mainly case reports and literature reviews. No prevalence study has been performed to date. Furthermore, disagreements persist regarding the semiology. Indeed, the involvement of the soft palate is not always described.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-08; most recent amendment 2025-09-09.
Status change: Enrolling by Invitation → Recruiting 2025-09-09
Trial Details
NCT Number NCT06033144
Lead Sponsor Hopital Forcilles
Conditions Tapia's Syndrome
Enrollment 247 participants
Start Date 2023-04-07
Primary Completion 2025-11-07 (estimated)
Study Completion 2027-04-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-15